Acticor Biotech SA
PAR:ALACT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Acticor Biotech SA
Cash from Financing Activities
Acticor Biotech SA
Cash from Financing Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
Acticor Biotech SA
PAR:ALACT
|
Cash from Financing Activities
€10.4m
|
CAGR 3-Years
218%
|
CAGR 5-Years
433%
|
CAGR 10-Years
N/A
|
|
|
Valneva SE
PAR:VLA
|
Cash from Financing Activities
-€621k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Cash from Financing Activities
€49m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Inventiva SA
PAR:IVA
|
Cash from Financing Activities
€241.3m
|
CAGR 3-Years
86%
|
CAGR 5-Years
17%
|
CAGR 10-Years
N/A
|
|
|
DBV Technologies SA
PAR:DBV
|
Cash from Financing Activities
$275.5m
|
CAGR 3-Years
13%
|
CAGR 5-Years
14%
|
CAGR 10-Years
1%
|
|
|
Abivax SA
PAR:ABVX
|
Cash from Financing Activities
€335.3m
|
CAGR 3-Years
118%
|
CAGR 5-Years
46%
|
CAGR 10-Years
N/A
|
|
Acticor Biotech SA
Glance View
Acticor Biotech SAS engages in the research and development of an antithrombotic agent for the treatment of the acute thrombotic diseases. The company is headquartered in Paris, Ile-De-France and currently employs 22 full-time employees. The company went IPO on 2021-11-01. The firm is a clinical stage biopharmaceutical company, a spin-off from INSERM (French National Institute of Health and Medical Research), specialized in the research and development of medicines for the treatment of thrombotic diseases, in particular acute ischemic strokes and pulmonary embolisms. The group has one product in Phase II clinical development (Glenzocimab) and its products in pipeline are ACTIMIS, GARDEN, ACTISAVE and GREEN. Its partnering companies are Ouest Valorisation, Genopole, Medicine and Inserm.
See Also
What is Acticor Biotech SA's Cash from Financing Activities?
Cash from Financing Activities
10.4m
EUR
Based on the financial report for Dec 31, 2023, Acticor Biotech SA's Cash from Financing Activities amounts to 10.4m EUR.
What is Acticor Biotech SA's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
433%
Over the last year, the Cash from Financing Activities growth was 40%. The average annual Cash from Financing Activities growth rates for Acticor Biotech SA have been 218% over the past three years , 433% over the past five years .
